Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GVAX with Nivolumab and Ipilimumab in Neuroblastoma
NCT04239040Phase 1Terminated
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jan 2020
- Primary completion
- Jan 2024
- Modality
- Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GVAX pancreatic cancer vaccine in neuroblastoma, sponsored by Dana-Farber Cancer Institute. Primary endpoints: Number of participants with grade 4 toxicities at 2 years and Number of Participants to receive 6 vaccinations at 2 years. Started Jan 2020; status: terminated.
02
Drugs
GVAX pancreatic cancer vaccine
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT04239040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04239040.